N-[4-(4-Methylpiperazin-1-ylcarbonyl)phenyl]-(2-chloro-5-nitrophenyl)carboxamide | 372095-32-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[4-(4-Methylpiperazin-1-ylcarbonyl)phenyl]-(2-chloro-5-nitrophenyl)carboxamide
• 英文别名: 2-chloro-N-[4-(4-methylpiperazine-1-carbonyl)phenyl]-5-nitrobenzamide
• CAS: 372095-32-4
• 化学式: C₁₉H₁₉ClN₄O₄
• 分子量: 402.837
• InChiKey: GVDQKZGXJORTFD-UHFFFAOYSA-N

物化性质

• 沸点：
  529.2±50.0 °C(Predicted)
• 密度：
  1.397±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  98.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4-[(4-甲基-1-哌嗪基)羰基]苯胺 、 2-氯-5-硝基苯甲酰氯 在 2,4-滴二甲胺盐 作用下， 以89%的产率得到N-[4-(4-Methylpiperazin-1-ylcarbonyl)phenyl]-(2-chloro-5-nitrophenyl)carboxamide
  参考文献：
  名称：

  PPAR-gamma modulator

  摘要：

  以下化学式的化合物或其药理学上可接受的盐：其中A代表苯基或类似物，B代表芳基或类似物，X代表氧原子或类似物，n代表0或1。该化合物是一种PPAR &ggr; 调节剂，用于治疗逆行性骨质疏松症，通过抑制脂肪细胞的过度分化并促进干细胞向成骨细胞的形成和分化，以及用于糖尿病而不具有过度脂肪生成、肝功能障碍、血管紊乱、心脏疾病等特征。

  公开号：

  US20030134859A1

文献信息

• PPAR (GAMMA) MODULATORS
  申请人：Sankyo Company, Limited

  公开号：EP1277729A1

  公开（公告）日：2003-01-22

  [Subject] The present invention has a purpose for providing a PPAR γ modulator which can be a therapeutic agent for retrograde osteoporosis in which excessive differentiation of adipocytes was inhibited and formation and differentiation of osteoblasts from stem cells is facilitated or that for diabetes mellitus without characteristics such as excessive adipogenesis, liver dysfunction, vascular disorders, heart diseases and the like. [Solution] A compound of the following formula or a pharmacologically acceptable salt thereof: wherein A represents a phenyl group or the like, B represents an aryl group or the like, X represents an oxygen atom or the like, and n represents 0 or 1.

  主题 本发明的目的在于提供一种PPAR γ调节剂，该调节剂可作为逆行性骨质疏松症的治疗药物，在逆行性骨质疏松症中，脂肪细胞的过度分化受到抑制，而干细胞的成骨细胞的形成和分化得到促进，或者可作为无过度脂肪生成、肝功能障碍、血管紊乱、心脏病等特征的糖尿病的治疗药物。 [解决方案］ 下式化合物或其药理学上可接受的盐： 其中 A 代表苯基或类似物，B 代表芳基或类似物，X 代表氧原子或类似物，n 代表 0 或 1。
• USE OF PPAR AGONISTS TO TREAT RUMINANTS
  申请人：Pfizer Products Incorporated

  公开号：EP1765320A2

  公开（公告）日：2007-03-28
• Use of Ppar Agonists to Treat Ruminants
  申请人：Goetze Franz Leopold

  公开号：US20070232647A1

  公开（公告）日：2007-10-04

  The use of a PPAR agonist in the manufacture of a medicament to increase ruminant serum glucose concentrations, and preferably, the use for the palliative, prophylactic or curative treatment of ruminant disease associated with reduced serum glucose concentration. The ruminant disease associated with reduced serum glucose concentration includes fatty liver syndrome, dystocia, immune dysfunction, impaired immune function, toxification, primary ketosis, secondary ketosis, downer cow syndrome, indigestion, inappetence, retained placenta, displaced abomasum, mastitis, (endo-)-metritis, infertility, low fertility, lameness, subacute rumen acidosis and inadequate nutrient intake associated with stress e.g. heat, poor housing, overcrowding, shipping, dominance or illness, and to increase milk quality and yield.
• [EN] NEW USE<br/>[FR] NOUVELLE UTILISATION
  申请人：PFIZER PROD INC

  公开号：WO2005115369A2

  公开（公告）日：2005-12-08

  The use of a PPAR agonist in the manufacture of a medicament to increase ruminant serum glucose concentrations, and preferably, the use for the palliative, prophylactic or curative treatment of ruminant disease associated with reduced serum glucose concentration. The ruminant disease associated with reduced serum glucose concentration includes fatty liver syndrome, dystocia, immune dysfunction, impaired immune function, toxif ication, primary ketosis, secondary ketosis, downer cow syndrome, indigestion, inappetence, retained placenta, displaced abomasum, mastitis, (endo-) -metritis, infertility, low fertility, lameness, subacute rumen acidosis and inadequate nutrient intake associated with stress e.g. heat, poor housing, overcrowding, shipping, dominance or illness, and to increase milk quality and yield.
• PPAR-gamma modulator
  申请人：SANKYO COMPANY, LIMITED

  公开号：US20030134859A1

  公开（公告）日：2003-07-17

  A compound of the following formula or a pharmacologically acceptable salt thereof: 1 wherein A represents a phenyl group or the like, B represents an aryl group or the like, X represents an oxygen atom or the like, and n represents 0 or 1. The compound is a PPAR &ggr; modulator which is a therapeutic agent for retrograde osteoporosis in which excessive differentiation of adipocytes is inhibited and formation and differentiation of osteoblasts from stem cells is facilitated, and for diabetes mellitus without characteristics such as excessive adipogenesis, liver dysfunction, vascular disorders, heart diseases and the like.

  以下化学式的化合物或其药理学上可接受的盐：其中A代表苯基或类似物，B代表芳基或类似物，X代表氧原子或类似物，n代表0或1。该化合物是一种PPAR &ggr; 调节剂，用于治疗逆行性骨质疏松症，通过抑制脂肪细胞的过度分化并促进干细胞向成骨细胞的形成和分化，以及用于糖尿病而不具有过度脂肪生成、肝功能障碍、血管紊乱、心脏疾病等特征。